Literature DB >> 24502305

Extramammary Paget disease successfully treated with topical imiquimod 5% and tazarotene.

Laura Frances1, Jose C Pascual, Maria Leiva-Salinas, Isabel Betlloch.   

Abstract

Extramammary Paget disease (EMPD) is an intraepithelial adenocarcinoma usually localized in areas rich in apocrine sweat glands. Surgery remains the treatment of choice for EMPD. However, several nonsurgical treatments have been also described. Around 40 cases of EMPD treated with imiquimod 5% have been published; of these, only six correspond to nonresponses. We describe a recurrent vulvar EMPD with failure to respond to topical imiquimod 5% in monotherapy but a favorable response to its association with tazarotene.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  extrammamary Paget disease; imiquimod; tazarotene

Mesh:

Substances:

Year:  2013        PMID: 24502305     DOI: 10.1111/dth.12030

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  2 in total

1.  Microarray-based identification of differentially expressed genes in extramammary Paget's disease.

Authors:  Jin-Ran Lin; Jun Liang; Qiao-An Zhang; Qiong Huang; Shang-Shang Wang; Hai-Hong Qin; Lian-Jun Chen; Jin-Hua Xu
Journal:  Int J Clin Exp Med       Date:  2015-05-15

Review 2.  Effects of imiquimod on vulvar Paget's disease: a systematic review of literature.

Authors:  Hiroko Machida; Aida Moeini; Lynda D Roman; Koji Matsuo
Journal:  Gynecol Oncol       Date:  2015-07-17       Impact factor: 5.482

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.